China
Africa
Explore chapters and articles related to this topic
Potential of Fenugreek in Management of Kidney and Lung Disorders
Published in Dilip Ghosh, Prasad Thakurdesai, Fenugreek, 2022
Amit D. Kandhare, Anwesha A. Mukherjee-Kandhare, Subhash L. Bodhankar
The underlying mechanism of fenugreek seeds’ powder is suggested in the study against STZ-induced diabetic nephropathy in experimental rats (Jin et al. 2014). Fenugreek powder was standardized to polysaccharides (0.74%) and administered in diabetic rats at a dose of 9 gm/kg orally. Various renal functions were evaluated including albuminuria, BUN, serum creatinine, kidney index, renal oxidative stress, and accumulation of extracellular matrix. Fenugreek treatment significantly inhibited STZ-induced alterations in renal functions and elevated oxidative stress (catalase, reduced glutathione (GHS) and MDA). Immunohistochemistry and quantitative (q) polymerase chain reaction analysis showed that upregulated fibronectin, type IV collagen, connective growth factor, and transforming growth factor-beta 1 (TGF-β1) were decreased by fenugreek treatment. These findings were further confirmed by western blot analysis of renal TGF-β1 protein expressions. Transmission electron microscopy suggested that STZ-induced glomerular morphological changes in kidneys were ameliorated by fenugreek treatment. Based on these findings, the authors concluded that fenugreek prevented development of renal toxicity via restrained TGF-β1/connective tissue growth factor (CTGF) signaling pathway STZ-induced diabetic nephropathy (Jin et al. 2014).
Tropical Herbs and Spices as Functional Foods with Antidiabetic Activities
Published in Megh R. Goyal, Arijit Nath, Rasul Hafiz Ansar Suleria, Plant-Based Functional Foods and Phytochemicals, 2021
Arnia Sari Mukaromah, Fitria Susilowati
Curcumin has the ability to enhance wound repair in diabetic patients. Sidhuetal. [91] evaluated the efficacy of curcumin for the treatment of wounds in diabetic rats. Wounds of rats treated with curcumin showed earlier re-epithe-lialization, accelerated neovascularization process, increased movement of various cells, including dermal myofibroblasts, fibroblasts, macrophages into the wound bed, and higher collagen content. For its immune-histochemical, the results showed an increase in transforming growth factor-beta 1 in curcumin-treated wounds compared to the control group. A delay in the apoptosis patterns was shown in diabetic wounds compared to curcumin-treated wounds [91].
Intelligent Nanomaterials for Medicine: Carrier Platforms and Targeting Strategies—State of the Art
Published in Lajos P. Balogh, Nano-Enabled Medical Applications, 2020
Georgette B. Salieb-Beugelaar, Marc Wolf, Roman Lehner, Kegang Liu, Stephan Marsch, Patrick Hunziker
Osteosarcoma stem cells are critically associated with the progression of osteosarcoma. Miao and coworkers demonstrated that SWNTs have (i) the ability to specifically inhibit the process of transforming growth factor beta 1 (TGFb1) induced osteosarcoma cell dedifferentiation, (ii) prevent the stem cell phenotypes acquisition in osteosarcoma cells, and (iii) to reduce the osteosarcoma stem cell viability under conditions that mimic the osteosarcoma microenvironment [73].
Collagen 3D matrices as a model for the study of cell behavior in pulmonary fibrosis
Published in Experimental Lung Research, 2022
Carlos Machahua, Vanesa Vicens-Zygmunt, Jesús Ríos-Martín, Roger Llatjós, Ignacio Escobar-Campuzano, María Molina-Molina, Ana Montes-Worboys
Among the different pro-fibrotic growth factors, transforming-growth factor beta-1 (TGF-β1) signaling is important for tissue growth and homeostasis.5 After a tissue injury, TGF-β1 acts increasing fibroblast recruitment, proliferation, differentiation into myofibroblasts and production of extracellular matrix.6 Stiff dysfunctional scar progressively and irreversibly replaces the normal lung parenchyma.7 Matrix stiffening per se can trigger the expression of collagens and other pro-fibrotic factors independently of TGF-β1, as well as myofibroblast differentiation, enhancing the pro-fibrotic microenvironment.8,9 We previously demonstrated that the matrix stiffness changes the pro-fibrotic response of lung cells.10
TGFB1 +869 T > C (rs1800470) variant is independently associated with susceptibility, laboratory activity, and TGF-β1 in patients with systemic lupus erythematosus
Published in Autoimmunity, 2021
Nicole Perugini Stadtlober, Tamires Flauzino, Lorena Flor da Rosa Franchi Santos, Tatiana Mayumi Veiga Iriyoda, Neide Tomimura Costa, Marcell Alysson Batisti Lozovoy, Edna Maria Vissoci Reiche, Andréa Name Colado Simão
Growing evidence has demonstrated that genetic variants in the coding and promoting regions of cytokine genes could affect cytokine production and, consequently may influence disease susceptibility and clinical manifestations [18,19]. In addition, it has been evaluated that TGFB1 genetic variants could reduce TGF-β1 plasma levels and predispose to autoimmune diseases, including SLE. Some studies evaluated the +869 T > C (rs1800470) and −509 C > T (rs1800469) TGFB1 genetic variants in SLE patients, and found an association with autoantibodies levels, susceptibility and clinical manifestations [12,20–22]. However, despite these studies, the data are still scarce and controversial. Thus, the study aimed to evaluate the association of the +869 T > C (rs1800470) and −509 C > T (rs1800469) TGFB1 variants, individually or in haplotype structure, with susceptibility, autoantibodies, disease activity, and TGF-β1 plasma levels in SLE patients.
Platelet-rich plasma loaded with antibiotics as an affiliated treatment for infected bone defect by combining wound healing property and antibacterial activity
Published in Platelets, 2021
Shaochuan Wang, Youbin Li, Shidan Li, Jing Yang, Ruohui Tang, Xiaoming Li, Lei Li, Jun Fei
To confirm the effects of different concentrations of different antibiotics on growth factors in PRP, the coagulant was first added to a sterile centrifuge tube containing PRP in a ratio of 1:10 to produce the PRG. Second, the tube was put in a thermostat and incubated for 10 min at 37°C to allow PRG to release growth factors. Next, the tube was centrifuged for 10 min at 3500 ×g. The final experimental supernatant was collected and mixed well. Some samples of the supernatant were obtained and frozen at −80°C to measure the concentration of growth factors as the concentration of PRP. Next, the fully mixed supernatant was divided into 10 tubes in aliquots followed by adding a certain dose of antibiotics to make up 10 groups: Groups 1–3 (1 mg, 10 mg, 100 mg vancomycin/mL), Groups 4–6 (1 mg, 10 mg, 100 mg clindamycin/mL), Groups 7–9 (1 mg, 10 mg, 100 mg ceftazidime/mL), Group10 (no drug, control). Within 15 min, the tubes were sealed with sealing tape and placed into a thermostat for incubation. After 1, 4, 8, 24, 48, and 72 h, an aliquot of sample was taken from each group and frozen at −80°C. Concentrations of growth factors containing transforming growth factor-beta 1 (TGF-β1) and platelet-derived growth factor-BB (PDGF-BB) of whole blood, PRP, PPP and every groups at certain time points were determined by enzyme-linked immunosorbent assay (ELISA) using TGF-β1 and PDGF-BB ELISA kits according to the manufacturer’s procedures.